Baseline carcinoembryonic antigen (CEA) serum levels predict bevacizumab-based treatment response in metastatic colorectal cancer

Cancer Science

Volumn 105, Issue 8, 2014, Pages 996-1001

  Prager, Gerald W ^a   Braemswig, Kira H ^a   Martel, Alexandra ^a   Unseld, Matthias ^a   Heinze, Georg ^a   Brodowicz, Thomas ^a   Scheithauer, Werner ^a   Kornek, Gabriela ^a   Zielinski, Christoph C ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Angiogenesis inhibitors; Bevacizumab; Biological markers; Carcinoembryonic antigen; Colorectal cancer

Indexed keywords

BEVACIZUMAB; BIOLOGICAL MARKER; CAPECITABINE; CARCINOEMBRYONIC ANTIGEN; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN; VASCULOTROPIN;

ADULT; AGED; ARTICLE; BLOOD LEVEL; CANCER CONTROL; CLINICAL ASSESSMENT; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; METASTATIC COLORECTAL CANCER; MIDDLE AGED; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; STATISTICAL ANALYSIS; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANGIOGENESIS INHIBITORS; BEVACIZUMAB; BIOLOGICAL MARKERS; CARCINOEMBRYONIC ANTIGEN; COLORECTAL CANCER;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 84906936377     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/cas.12451     Document Type: Article

References (32)

1. Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-42.
2. Miller K, Wang M, Gralow J et al. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007; 357: 2666-76.
3. Reck M, von PJ, Zatloukal P et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAil. J Clin Oncol 2009; 27: 1227-34.
4. Fischer C, Mazzone M, Jonckx B, Carmeliet P. FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? Nat Rev Cancer 2008; 8: 942-56.
5. Cassidy J, Clarke S, az-Rubio E et al. Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil/folinic acid plus oxaliplatin as first-line therapy for metastatic colorectal cancer. J Clin Oncol 2008; 26: 2006-12.
6. Saltz LB, Clarke S, az-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-9.
7. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005; 438: 932-6.
8. Bramswig KH, Poettler M, Kalinowska W et al. CEA affects tumor- angiogenesis via integrin beta3- dependent activation of endothelial cells. Cancer Res 2013; 73: 6584-96.
9. Ordonez C, Screaton RA, Ilantzis C, Stanners CP. Human carcinoembryonic antigen functions as a general inhibitor of anoikis. Cancer Res 2000; 60: 3419-24.
10. Samara RN, Laguinge LM, Jessup JM. Carcinoembryonic antigen inhibits anoikis in colorectal carcinoma cells by interfering with TRAIL-R2 (DR5) signaling. Cancer Res 2007; 67: 4774-82.
11. Gold P, Freedman SO. Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med 1965; 121: 439-62.
12. Iwanicki-Caron I, Di FF, Roque I et al. Usefulness of the serum carcinoembryonic antigen kinetic for chemotherapy monitoring in patients with unresectable metastasis of colorectal cancer. J Clin Oncol 2008; 26: 3681-6.
13. Nollau P, Scheller H, Kona-Horstmann M et al. Expression of CD66a (human C-CAM) and other members of the carcinoembryonic antigen gene family of adhesion molecules in human colorectal adenomas. Cancer Res 1997; 57: 2354-7.
14. Ellis LM, Hicklin DJ. Pathways mediating resistance to vascular endothelial growth factor-targeted therapy. Clin Cancer Res 2008; 14: 6371-5.
15. Ocvirk J, Brodowicz T, Wrba F et al. Cetuximab plus FOLFOX6 or FOLFIRI in metastatic colorectal cancer: CECOG trial. World J Gastroenterol 2010; 16: 3133-43.
16. Eisenhauer EA, Therasse P, Bogaerts J et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
17. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med 2006; 25(1): 127-41.
18. Cox DR. Regression models and life-tables. J R Stat Soc B 1972; 34: 187-220.
19. Royston P, Sauerbrei W. Multivariable Model-building - A Pragmatic Approach to Regression Analysis Based on Fractional Polynomials for Modelling Continuous Variables. Chichester: Wiley, 2008.
20. Kaplan EL, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-81.
21. Webb A, Scott-Mackie P, Cunningham D et al. The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer. Ann Oncol 1995; 6: 581-7.
22. Strimpakos AS, Cunningham D, Mikropoulos C, Petkar I, Barbachano Y, Chau I. The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy. Ann Oncol 2010; 21: 1013-9.
23. Carmeliet P, Jain RK. Angiogenesis in cancer and other diseases. Nature 2000; 407: 249-57.
24. Bais C, Wu X, Yao J et al. PlGF blockade does not inhibit angiogenesis during primary tumor growth. Cell 2010; 141(1): 166-77.
25. Van CE, Lambrechts D, Prenen H, Jain RK, Carmeliet P. Lessons from the adjuvant bevacizumab trial on colon cancer: what next? J Clin Oncol 2011; 29(1): 1-4.
26. Goede V, Coutelle O, Neuneier J et al. Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy. Br J Cancer 2010; 103: 1407-14.
27. Lambrechts D, Lenz HJ, de Haas S, Carmeliet P, Scherer SJ. Markers of response for the antiangiogenic agent bevacizumab. J Clin Oncol 2013; 31(9): 1219-30.
28. Zhang W, Azuma M, Lurje G et al. Molecular predictors of combination targeted therapies (cetuximab, bevacizumab) in irinotecan-refractory colorectal cancer (BOND-2 study). Anticancer Res 2010; 30: 4209-17.
29. Sargent DJ, Conley BA, Allegra C, Collette L. Clinical trial designs for predictive marker validation in cancer treatment trials. J Clin Oncol 2005; 23: 2020-7.
30. Ordonez C, Zhai AB, Camacho-Leal P, Demarte L, Fan MM, Stanners CP. GPI-anchored CEA family glycoproteins CEA and CEACAM6 mediate their biological effects through enhanced integrin alpha5beta1-fibronectin interaction. J Cell Physiol 2007; 210: 757-65.
31. Hostetter RB, Augustus LB, Mankarious R et al. Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis. J Natl Cancer Inst 1990; 82: 380-5.
32. Takagawa R, Fujii S, Ohta M et al. Preoperative serum carcinoembryonic antigen level as a predictive factor of recurrence after curative resection of colorectal cancer. Ann Surg Oncol 2008; 15: 3433-9.